ArriVent BioPharma Files 8-K

Ticker: AVBP · Form: 8-K · Filed: Jun 23, 2025 · CIK: 1868279

Arrivent Biopharma, INC. 8-K Filing Summary
FieldDetail
CompanyArrivent Biopharma, INC. (AVBP)
Form Type8-K
Filed DateJun 23, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, 8-k

TL;DR

ArriVent BioPharma filed a routine 8-K on 6/23/25. No major news.

AI Summary

ArriVent BioPharma, Inc. filed an 8-K on June 23, 2025, reporting on other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates ArriVent BioPharma is meeting its regulatory reporting obligations. Investors should review the details within the filing for any specific operational updates or financial disclosures.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not disclose any new material risks or significant negative events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for ArriVent BioPharma, Inc.?

The primary purpose of this 8-K filing, dated June 23, 2025, is to report on 'Other Events' and 'Financial Statements and Exhibits' as per SEC regulations.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is June 23, 2025.

In which state was ArriVent BioPharma, Inc. incorporated?

ArriVent BioPharma, Inc. was incorporated in Delaware.

What is the principal executive office address for ArriVent BioPharma, Inc.?

The principal executive office address is 18 Campus Boulevard, Suite 100, Newtown Square, PA 19073.

What is the SIC code for ArriVent BioPharma, Inc.?

The Standard Industrial Classification (SIC) code for ArriVent BioPharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 23, 2025 regarding ArriVent BioPharma, Inc. (AVBP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing